Eupraxia Pharmaceuticals Inc
(EPRX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,221 | -6,157 | -28,966 | -18,359 | -13,463 |
| Depreciation Amortization | 79 | 37 | 156 | 114 | 76 |
| Accounts receivable | 31 | 17 | -104 | 21 | 38 |
| Other Working Capital | -2,594 | 250 | 5,352 | -164 | -448 |
| Other Operating Activity | 872 | -285 | 2,878 | 3,604 | 4,957 |
| Operating Cash Flow | $-13,833 | $-6,137 | $-20,684 | $-14,784 | $-8,839 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 11 | -7 | -73 | -24 | -14 |
| Investing Cash Flow | $11 | $-7 | $-73 | $-24 | $-14 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -4,495 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 337 | 337 | 5,272 | 5,246 | 4,825 |
| Other Financing Activity | 22,812 | 22,833 | 15,742 | 15,827 | -39 |
| Financing Cash Flow | $18,654 | $23,170 | $21,014 | $21,073 | $4,786 |
| Exchange Rate Effect | -858 | -461 | 821 | 35 | 228 |
| Beginning Cash Position | 19,342 | 19,342 | 18,263 | 18,263 | 18,263 |
| End Cash Position | 23,316 | 35,908 | 19,342 | 24,564 | 14,423 |
| Net Cash Flow | $3,974 | $16,566 | $1,078 | $6,300 | $-3,841 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,833 | -6,137 | -20,684 | -14,784 | -8,839 |
| Capital Expenditure | -18 | -7 | -73 | -24 | -14 |
| Free Cash Flow | -13,850 | -6,144 | -20,757 | -14,808 | -8,854 |